Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 7868 792050

Feilai Xie

Department of Pathology, Dongfang Hospital of Xiamen University, Fuzhou General Hospital of Fujian Medical University, The 900th Hospital of the Joint Logistic Support Force, Fuzhou, China

  • Research   
    Lung Adenocarcinoma with Active Aulmonary Tuberculosis: A Case Report of Successful Immunotherapy and Systematical Review
    Author(s): Jinhe Xu, Xiuhua Lin, Wei Liu, Jia Ye, Zongyang Yu*, Feilai Xie, Huimin Deng and Ming Deng

    Background: Immune Checkpoint Inhibitors (ICIs) have become widely used in the treatment of several malignancies, and get better clinical benefits in some patients with Non-Small Cell Lung Cancer (NSCLC). However, in most of high quality clinical Randomized Controlled Trial (RCT) studies, only selected patients are needed. In Real-World Study (RWS), patients contracted simultaneously with NSCLC and Tuberculosis is common. TB reactivation during ICIs use is increasingly recognized and reported. Whether ICIs can be used in anti-tumor in patients with TB is rarely seen. Case presentation: Herein, we present a 67-year-old male active tuberculosis complicated with advanced Non-Small Cell Lung Cancer (NSCLC) ALK-negative, EGFR wild, and PD-L1 Immune Histochemistry (IHC) strongly positive in 60%-90% of tumor cells, on ongoing treatment with Pembrol.. View More»

    Abstract HTML PDF